Partnerships

Collaborate. Innovate. Deliver. Cure.

A truly multidisciplinary solution, IMITA® has only been made possible through Captixbio’s collaborations with these leading research organisations.

UNSW Sydney

UNSW Sydney

UNSW Sydney is one of Australia’s leading research universities, encompassing strong engagement both regionally and on a global scale.

Captixbio and UNSW are actively collaborating on different fronts including device designs, polymers, and implantation strategy. The partnership allows both entities to share knowledge, debate, and research outcomes to achieve the desired results.

https://www.unsw.edu.au/

Queensland University of Technology (QUT)

Queensland University of Technology (QUT)

The mission of QUT’s Medical Engineering Research Facility (MERF) is “to make a positive difference to people’s lives by improving health care through clinically relevant research and training”. MERF is a NATA recognised, GLP compliant facility designed to meet Australia’s emerging needs in musculoskeletal and critical care research. MERF includes world-class surgical theatres, animal holding areas and long term agistment facilities, as well as research laboratories, providing a comprehensive suite of research and training facilities at the one location.

Captixbio is undertaking contract research with MERF, whose highly experienced team of researchers and technical staff provide support to conduct preclinical research for the development of new techniques, materials, devices and procedures.

https://www.qut.edu.au/

St Vincent’s Institute of Medical Research

St Vincent’s Institute of Medical Research

St Vincent’s Institute of Medical Research (SVI), based in Melbourne, Victoria, is one of Australia’s leading medical research institutes. SVI carries out medical research into the cause, prevention and treatment of diseases that are common and have serious effects on health. As part of this remit, researchers at SVI are dedicated to finding effective prevention and treatment strategies for type 1 diabetes. SVI is intimately involved in the Australian Islet Transplant Program, in which people with uncontrollable diabetes are transplanted with human islets. The Victorian arm of the Program, led by SVI, has resulted in more than 40 diabetic patients receiving transplants to date.

SVI has provided advisory services and expert input into Captixbio’s research programs since the company was founded in 2018 and is now also providing specialist research services, providing high quality data and scientific analysis to support decision making and product development.

www.svi.edu.au

Commonwealth Scientific and Industrial Research Organisation, CSIRO

Commonwealth Scientific and Industrial Research Organisation, CSIRO

As Australia’s national science agency and innovation catalyst, the Commonwealth Scientific and Industrial Research Organisation (CSIRO) solves the greatest challenges through innovative science and technology. CSIRO works with organisations large and small, delivering world-leading research and development solutions to help businesses innovate, improve, and grow.

Captixbio and CSIRO are collaborating to develop, optimise and manufacture a selectively porous, implantable, immuno-protective polymer membrane. Captixbio is a recipient of funding through CSIRO’s Kickstart program.

www.csiro.au

University of Sydney: Thorn Lab

University of Sydney: Thorn Lab

The University of Sydney’s founding principle was that it would be a modern and progressive institution, an ideal it still holds dear today. Progressive thinking, breaking with convention, challenging the status quo and improving the world around us are values held by both Captixbio and the University. The Thorn Lab, led by Professor Peter Thorn, based at the Charles Perkins Research Centre, has developed and implemented cutting-edge technologies to understand how insulin secretion is regulated within pancreatic islets in health & disease.

Captixbio is fortunate to be able to work with Professor Thorn and his team, leveraging their skills and insight to research how its technology interacts with beta-cells, impacts islet function, and to evaluate and refine its approach to cell-based therapies to cure diabetes. Captixbio is also the grateful recipient of CDIP and Boosting Innovation grants through the University of Sydney that have helped to support this work.

https://www.sydney.edu.au/
http://www.thornlab.com/

OneFourNine Consulting

OneFourNine Consulting

OneFourNine is a consultancy, founded by Helen Souris, dedicated to helping start up and scale up innovators in MedTech and Biotech realise their potential through strategies and execution based on evidence. Helen’s focus is on supporting health and medical innovations that improve patient’s lives. Her background in statistics and computer science, along with an in depth understanding of the data needed to drive clinical and commercial outcomes, sets her apart at this important intersection of scientific, clinical and corporate development.

Captixbio™ is pleased to be working with OneFourNine Consulting to develop an in depth understanding of the patient experience and of clinical insights to more effectively guide product development. A common drive to deliver tangible outcomes for patients with Type 1 makes the partnership between OneFourNine Consulting and Captixbio that much more rewarding.

https://www.onefournine.com.au/

McBain Family Trust

McBain Family Trust

Captixbio is grateful to be the recipient of equity investments and ongoing financial support from the McBain Family Trust.